Dr David U’Prichard joined the Board of Directors of Oxagen in May 2004. He is currently President of Druid Consulting LLC, a pharmaceutical and biotechnology-consulting firm, providing customized services to life sciences clients in the United States and Europe. He is also a Venture Partner with Care Capital LLP and Red Abbey Venture Partners, private equity providers.

Previously David was Chief Executive Officer of 3-Dimensional Pharmaceuticals, Inc. from 1999 to 2003. In addition, he held a variety of positions within the pharmaceutical and biotechnology industries, including, President and Chairman of Research and Development for SmithKline Beecham Pharmaceuticals; Executive Vice President and International Research Director, and a Member of the Board of Zeneca Pharmaceuticals; General Manager, Research Department, ICI Pharmaceuticals, and Vice President Biomedical Research, ICI Pharmaceuticals; and Senior Vice President and Scientific Director for Nova Pharmaceutical Corporation.

At board level, David is a director of Invitrogen Corp. and non-executive Chairman of Cyclacel. He was Chairman of the Pennsylvania Biotechnology Association in 2004-2005 and from 1992 to 1997 he was a member of the board of the Biotechnology Industry Organization (BIO).

David received a BSc in Pharmacology from University of Glasgow in 1970 and a PhD in Pharmacology from University of Kansas in 1975.